Anticancer effect and mechanism of miR-139

doi:10.3760/cma.j.issn.1673-422X.2016.10.010

Abstract

Abstract: MicroRNA (miRNA) is closely related to the occurrence and development of neoplasms. miR139 is a tumorsuppressive miRNA and its expression is decreased in a variety of tumor tissues, while overexpression of miR139 can inhibit cancer cell proliferation, migration, invasion and induce cell apoptosis by suppressing the expression of multiple kinds of target genes. Therefore, miR139 has potential applications in tumor diagnosis, treatment and prognosis assessment.

Key words: MicroRNAs, Neoplasms, Target gene

Zhai Junshan, Li Nan. Anticancer effect and mechanism of miR-139[J]. Journal of International Oncology, 2016, 43(10): 765-768.

References

［1］ Liu B, Li J, Cairns MJ. Identifying miRNAs, targets and functions［J］. Brief Bioinform, 2014, 15(1): 1-19. DOI: 10.1093/bib/bbs075. ［2］ Sun C, Sang M, Li S, et al. HsamiR1395p inhibits proliferation and causes apoptosis associated with downregulation of cMet［J］. Oncotarget, 2015, 6(37): 39756-39792. DOI: 10.18632/oncotarget.5476. ［3］ Radfar MH, Wong W, Morris Q. Computational prediction of intronic microRNA targets using host gene expression reveals novel regulatory mechanisms［J］. PLoS One, 2011, 6(6): e19312. DOI: 10.1371/journal.pone.0019312. ［4］ Ozsolak F, Poling LL, Wang Z, et al. Chromatin structure analyses identify miRNA promoters［J］. Genes Dev, 2008, 22(22): 3172-3183. DOI: 10.1101/gad.1706508. ［5］ Shen K, Mao R, Ma L, et al. Posttranscriptional regulation of the tumor suppressor miR1395p and a network of miR1395pmediated mRNA interactions in colorectal cancer［J］. FEBS J, 2014, 281(16): 3609-3624. DOI: 10.1111/febs.12880. ［6］ Bao W, Fu HJ, Xie QS, et al. HER2 interacts with CD44 to upregulate CXCR4 via epigenetic silencing of microRNA139 in gastric cancer cells［J］. Gastroenterology, 2011, 141(6): 2076-2087.e6. DOI: 10.1053/j.gastro.2011.08.050. ［7］ Watanabe K, Amano Y, Ishikawa R, et al. Histone methylationmediated silencing of miR139 enhances invasion of nonsmallcell lung cancer［J］. Cancer Med, 2015, 4(10): 1573-1582. DOI: 10.1002/cam4.505. ［8］ Zhang L, Dong Y, Zhu N, et al. microRNA1395p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancer［J］. Mol Cancer, 2014, 13: 124. DOI: 10.1186/1476459813124. ［9］ Guo H, Hu X, Ge S, et al. Regulation of RAP1B by miR139 suppresses human colorectal carcinoma cell proliferation［J］. Int J Biochem Cell Biol, 2012, 44(9): 1465-1472. DOI: 10.1016/j.biocel.2012.05.015. ［10］ Shen K, Liang Q, Xu K, et al. MiR139 inhibits invasion and metastasis of colorectal cancer by targeting the type Ⅰ insulinlike growth factor receptor［J］. Biochem Pharmacol, 2012, 84(3): 320-330. DOI: 10.1016/j.bcp.2012.04.017. ［11］ Song M, Yin Y, Zhang J, et al. MiR1395p inhibits migration and invasion of colorectal cancer by downregulating AMFR and NOTCH1［J］. Protein Cell, 2014, 5(11): 851-861. DOI: 10.1007/s1323801400935. ［12］ Wong CC, Wong CM, Tung EK, et al. The microRNA miR139 suppresses metastasis and progression of hepatocellular carcinoma by downregulating Rhokinase 2［J］. Gastroenterology, 2011, 140(1): 322-331. DOI: 10.1053/j.gastro.2010.10.006. ［13］ Fan Q, He M, Deng X, et al. Derepression of cFos caused by microRNA139 downregulation contributes to the metastasis of human hepatocellular carcinoma［J］. Cell Biochem Funct, 2013, 31(4): 319-324. DOI: 10.1002/cbf.2902. ［14］ Gu W, Li X, Wang J. miR139 regulates the proliferation and invasion of hepatocellular carcinoma through the WNT/TCF4 pathway［J］. Oncol Rep, 2014, 31(1): 397-404. DOI: 10.3892/or.2013.2831. ［15］ Qiu G, Lin Y, Zhang H, et al. miR1395p inhibits epithelialmesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2［J］. Biochem Biophys Res Commun, 2015, 463(3): 315-321. DOI: 10.1016/j.bbrc.2015.05.062. ［16］ Guo J, Miao Y, Xiao B, et al. Differential expression of microRNA species in human gastric cancer versus nontumorous tissues［J］. J Gastroenterol Hepatol, 2009, 24(4): 652-657. DOI: 10.1111/j.14401746.2008.05666.x. ［17］ Kang HS, Kim J, Jang SG, et al. MicroRNA signature for HER2positive breast and gastric cancer［J］. Anticancer Res, 2014, 34(7): 3807-3810. . ［18］ Zhang Y, Shen WL, Shi ML, et al. Involvement of aberrant miR139/Jun feedback loop in human gastric cancer［J］. Biochim Biophys Acta, 2015, 1853(2): 481-488. DOI: DOI: 10.1016/j.bbamcr.2014.12.002. ［19］ Krishnan K, Steptoe AL, Martin HC, et al. miR1395p is a regulator of metastatic pathways in breast cancer［J］. RNA, 2013, 19(12): 1767-1780. DOI: 10.1261/rna.042143.113. ［20］ Rask L, Balslev E, Skilde R, et al. Differential expression of miR139, miR486 and miR21 in breast cancer patients subclassified according to lymph node status［J］. Cell Oncol (Dordr), 2014, 37(3): 215-227. DOI: 10.1007/s1340201401766. ［21］ Hua W, Sa KD, Zhang X, et al. MicroRNA139 suppresses proliferation in luminal type breast cancer cells by targeting topoisomerase Ⅱ alpha［J］. Biochem Biophys Res Commun, 2015, 463(4): 1077-1083. DOI: 10.1016/j.bbrc.2015.06.061. ［22］ Zhang HD, Sun DW, Mao L, et al. MiR1395p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel［J］. Biochem Biophys Res Commun, 2015, 465(4): 702-713. DOI: 10.1016/j.bbrc.2015.08.053. ［23］ Luo HN, Wang ZH, Sheng Y, et al. MiR139 targets CXCR4 and inhibits the proliferation and metastasis of laryngeal squamous carcinoma cells［J］. Med Oncol, 2014, 31(1): 789. DOI: 10.1007/s120320130789z. ［24］ Liu R, Yang M, Meng Y, et al. Tumorsuppressive function of miR1395p in esophageal squamous cell carcinoma［J］. PLoS One, 2013, 8(10): e77068. DOI: 10.1371/journal.pone.0077068. ［25］ Dai S, Wang X, Li X, et al. MicroRNA1395p acts as a tumor suppressor by targeting ELTD1 and regulating cell cycle in glioblastoma multiforme［J］. Biochem Biophys Res Commun, 2015, 467(2): 204-210. DOI: 10.1016/j.bbrc.2015.10.006. ［26］ Emmrich S, Engeland F, ElKhatib M, et al. miR1395p controls translation in myeloid leukemia through EIF4G2［J］. Oncogene, 2016, 35(14): 1822-1831. DOI: 10.1038/onc.2015.247. ［27］ Zhang HD, Jiang LH, Sun DW, et al. MiR1395p: promising biomarker for cancer［J］. Tumour Biol, 2015, 36(3): 1355-1365. DOI: 10.1007/s1327701531993.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.